Surender Deora¹ and Surendra Kumar Verma²*

¹Additional Professor of Cardiology, All India Institute of Medical Sciences (AIIMS), Jodhpur (Raj), India
²Professor Emeritus and Director, Department of Medicine, Pacific Medical College and Hospitals, Udaipur (Raj), India

*Corresponding Author: Surendra Kumar Verma, Professor Emeritus and Director, Department of Medicine, Pacific Medical College and Hospitals, Udaipur (Raj), India.

Received: June 15, 2022; Published: July 06, 2022

Abstract

Introduction: Erectile dysfunction is predominantly a vascular disease and may even be a marker for occult-cardiovascular disease. There are reports that PDE5 inhibitors inhibit platelet aggregation in animal models and only few studies presenting in vitro data of human platelet modulation by PDE type-5 inhibitor Sildenafil. The present study therefore, was planned to evaluate effect of long-acting phosphodiesterase type-5 inhibitor, tadalafil on human platelet aggregation.

Methods: The study was conducted on 30 healthy male volunteers between the age of 30 to 50 years. Tadalafil 10 mg and 20 mg was given to 15 patients in each group. Blood samples were collected after four and twenty-four hours of drug administration. All blood samples were subjected for the estimation of platelet aggregation on ELVI-840 aggregometer and Omni scribe chart recorded.

Results: Administration of Tadalafil has decreased platelet aggregation after 4 hrs and 24 hrs; which in both the cases was statistically significant. However, the decrease in platelet aggregation at the end of 24 hrs as compared to 4 hrs was not significant.

Conclusion: Tadalafil is effective inhibitor of platelet aggregation induced by ADP and collagen. Collagen induced aggregation is more significantly blocked by Tadalafil. The dose of 20 mg is more effective in inhibition of platelet aggregation at 24 hours as compared to 10 mg.

Keywords: Phosphodiesterases; cGMP; cAMP; NO; Erectile dysfunction

References

1. Feldman HA., et al. “Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study”. Journal of Urology1 (1994): 54-61.
2. Beavo JA. “Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms”. Physiology Review4 (1995): 725-748.
3. Wallis RM., et al. “Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro”. American Journal of Cardiology5A (1999): 3C-12C.
4. Reffelmann T and Kloner RA. “Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease”. Circulation 2 (2003): 239-244.
5. Nicholson CD., et al. “Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes”. Trends in Pharmacology Science 1 (1991): 19-27.
6. Walter U., et al. “Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets”. Advances in Experimental Medicine and Biology 344 (1993): 237-249.
7. Maurice DH and Haslam RJ. “Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP”. Molecular Pharmacology5 (1990): 671-681.
8. Vemulapalli S., et al. “In vivo inhibition of platelet adhesion by a cGMP-mediated mechanism in balloon catheter injured rat carotid artery”. Pharmacology4 (1996): 235-242.
9. Chiu PJ., et al. “Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigs”. Naunyn-Schmiedeberg's Archives of Pharmacology 4 (1997): 463-469.
10. Berkels R., et al. “Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil”. Journal of Cardiovascular Pharmacology4 (2001): 413-421.
11. Verma SK and Jain P. “Sildenafil and human platelet aggregation”. Journal of the American College of Angiology 1 (2003): 334-341.
12. Sly MK., et al. “Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors”. Shock2 (1997): 115-118.
13. Li Z., et al. “A stimulatory role for cGMP-dependent protein kinase in platelet activation”. Cell1 (2003): 77-86.

Citation

Citation: Surender Deora and Surendra Kumar Verma. “Effect of Long - Acting Phosphodiesterase Type-5 Inhibitor - Tadalafil on Human Platelet Aggregation”.Acta Scientific Medical Sciences 6.8 (2022): 04-09.

Copyright

Copyright: © 2022 Surender Deora and Surendra Kumar Verma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.